---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004824"
form_type: "8-K"
ticker: "INGN"
cik: "0001294133"
company_name: "Inogen Inc"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:55:23.518927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance

## Summary
- Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.
- Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.
- Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.
- Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.
- Official Q4/FY results and conference call scheduled for Feb 25, 2025.

## SEC filing metadata
- accession: 0000950170-25-004824
- form_type: 8-K
- ticker: INGN
- cik: 0001294133
- company_name: Inogen Inc
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/0000950170-25-004824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1294133/000095017025004824/ingn-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004824
- JSON: https://secwatch.observer/filing/0000950170-25-004824.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.